BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17296563)

  • 1. Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia.
    Roman-Gomez J; Jimenez-Velasco A; Agirre X; Castillejo JA; Navarro G; San Jose-Eneriz E; Garate L; Cordeu L; Cervantes F; Prosper F; Heiniger A; Torres A
    Haematologica; 2007 Feb; 92(2):153-62. PubMed ID: 17296563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent expression of HAGE in presentation chronic myeloid leukaemias.
    Adams SP; Sahota SS; Mijovic A; Czepulkowski B; Padua RA; Mufti GJ; Guinn BA
    Leukemia; 2002 Nov; 16(11):2238-42. PubMed ID: 12399967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia.
    Roman-Gomez J; Jimenez-Velasco A; Agirre X; Cervantes F; Sanchez J; Garate L; Barrios M; Castillejo JA; Navarro G; Colomer D; Prosper F; Heiniger A; Torres A
    Oncogene; 2005 Nov; 24(48):7213-23. PubMed ID: 16170379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia].
    Yang H; Yan JS; Tao R; Hao SG; Liang H; Ma LY
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):169-75. PubMed ID: 22780968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
    Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
    Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.
    San José-Eneriz E; Agirre X; Jiménez-Velasco A; Cordeu L; Martín V; Arqueros V; Gárate L; Fresquet V; Cervantes F; Martínez-Climent JA; Heiniger A; Torres A; Prósper F; Roman-Gomez J
    Eur J Cancer; 2009 Jul; 45(10):1877-89. PubMed ID: 19403302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression of helicase antigen in patients with acute and chronic myeloid leukemia.
    Chen Q; Lin J; Qian J; Yao DM; Qian W; Li Y; Chai HY; Yang J; Wang CZ; Zhang M; Xiao GF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1171-5. PubMed ID: 22040965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
    Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABCB1 regulation through LRPPRC is influenced by the methylation status of the GC -100 box in its promoter.
    Corrêa S; Binato R; Du Rocher B; Ferreira G; Cappelletti P; Soares-Lima S; Pinto LF; Mencalha A; Abdelhay E
    Epigenetics; 2014 Aug; 9(8):1172-83. PubMed ID: 25089713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib induces demethylation of miR-203 gene: an epigenetic mechanism of anti-tumor effect of imatinib.
    Shibuta T; Honda E; Shiotsu H; Tanaka Y; Vellasamy S; Shiratsuchi M; Umemura T
    Leuk Res; 2013 Oct; 37(10):1278-86. PubMed ID: 23953880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic regulation of PRAME gene in chronic myeloid leukemia.
    Roman-Gomez J; Jimenez-Velasco A; Agirre X; Castillejo JA; Navarro G; Jose-Eneriz ES; Garate L; Cordeu L; Cervantes F; Prosper F; Heiniger A; Torres A
    Leuk Res; 2007 Nov; 31(11):1521-8. PubMed ID: 17382387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Research on the epigenetic regulation mechanism of the PTPN6 gene in advanced chronic myeloid leukaemia.
    Zhang X; Yang L; Liu X; Nie Z; Wang X; Pan Y; Luo J
    Br J Haematol; 2017 Sep; 178(5):728-738. PubMed ID: 28480959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent.
    Kim SH; Kim D; Kim DW; Goh HG; Jang SE; Lee J; Kim WS; Kweon IY; Park SH
    Hematol Oncol; 2009 Dec; 27(4):190-7. PubMed ID: 19274615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Research advance on molecular genetics of CML blast crisis].
    Zhu HQ; Zhang S; Liu XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia.
    Ernst T; Hoffmann J; Erben P; Hehlmann R; Hochhaus A; Müller MC
    Clin Chem Lab Med; 2008; 46(3):318-22. PubMed ID: 18303987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro].
    Wang XD; Qiu L; Lu RZ; Chen LJ; Zhan ZM; Han BH; Zhang BL; Ma J
    Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3399-405. PubMed ID: 18476538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The methylation status of the DDX43 promoter in Chinese patients with chronic myeloid leukemia.
    Chen Q; Lin J; Qian J; Deng ZQ; Qian W; Yang J; Li Y; Chen XX; Ma YJ; Ma JC; Liu Q
    Genet Test Mol Biomarkers; 2013 Jun; 17(6):508-11. PubMed ID: 23495895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted chronic myeloid leukemia therapy: Seeking a cure.
    Fausel C
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
    Cohen MH; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.